Navigation Links
Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent

MALVERN, Pa. and SHANGHAI, Feb. 23 /PRNewswire/ -- Frontage Laboratories Inc. ("Frontage"), a leading high quality provider of bioanalytical, pre-clinical, clinical and drug development services to global pharmaceutical companies, is pleased to announce it has expanded its research and development agreement with Beijing Second Pharmaceuticals, the ethical drug division of Beijing Pharmaceutical Group ("Beijing Pharma"), to accelerate Beijing Pharma's entrance into the international generic drug market. In addition, Frontage recently hired Len Stigliano as Chief Financial Officer and Derek (Yuanchao) Zhang, Ph.D. as Vice President of Regulatory Affairs and Clinical Pharmacology. These investments further strengthen Frontage's market leadership as a U.S.-China contract research organization.

The agreement with Beijing Pharmaceuticals is a further expansion of Frontage's current relationship with this client and its overall business in China. As part of the agreement, Frontage will obtain a newly constructed, 1,800 sq.meter R&D center and continued access to Beijing Pharma's GMP manufacturing areas. Frontage will also collaborate with Beijing Pharma to develop 12 ANDA products over the next 3-5 years, which will be marketed in China, Europe and the U.S. Frontage has been operating in China for 3 years, and serves both global and Chinese pharmaceutical customers. In 2007, Frontage helped Beijing Pharma in designing, renovating, and commissioning its manufacturing facilities to meet U.S. FDA and ICH GMP requirements, in building its GMP systems, employee training and in product development efforts. One of the products developed through the relationship has been filed to the U.S. FDA in 2008, with several more targeted for filing in 2009. European authorities successfully inspected the facilities in 2008.

"This partnership demonstrates our continued commitment to support the U.S., European and Chinese companies' development programs in generic drugs, and to help them gain access to international markets," said Song Li, President and CEO of Frontage. "We are pleased that the investments we have made in our business over the last year are being recognized by our customers and partners."

As further evidence of the company's growth, Frontage recently hired Len Stigliano as CFO and Derek Zhang as VP of Regulatory Affairs and Clinical Pharmacology. Stigliano, a 25 year financial professional in the life sciences business was most recently the CFO of Novavax, a publicly traded novel vaccine development company. Dr. Zhang brings to Frontage over 10 years of combined experience in the areas of drug research, development and regulatory approval, including four years of experience at Pfizer and six years of regulatory experience at the U.S. Food and Drug Administration.

"We are extremely pleased to welcome Len and Derek to Frontage," said Brett Tucker, Partner with Baird Capital Partners Asia, an investor in Frontage. "Len brings a broad base of financial experience and global expertise to Frontage, and Derek brings a solid reputation among the regulatory and clinical pharmacology community in the U.S. and China. These investments will only help us serve our global customer base better."

Biography - Len Stigliano

Stigliano has over 25 years of experience and proven success at publicly traded healthcare and life sciences companies both as a senior operating and financial executive. He has been instrumental in driving revenues, growth, drug development, profitability and operational performance at each of these companies, including a leading contract research organization during its high growth phase. Stigliano was most recently Chief Financial Officer of Novavax, a publicly traded novel vaccine development company. Prior to that he held various senior financial and operating roles within Omnicare Clinical Research, Inc., where he was eventually responsible for global operations of over $145 million of annual revenue. At Omnicare he also oversaw over 800 employees worldwide, and implemented new systems and processes for the company's global drug development operations, including the oversight of all clinical trials, project management, and project profitability. He is a Certified Public Accountant, received his BA from Rutgers University and his MBA from Pace University.

Biography - Dr. Derek Zhang

Dr. Zhang has 10 years of combined experience in the areas of drug research, development and regulatory approval, including four years of industrial experience at Pfizer and six years of regulatory experience at U.S. FDA. Derek was Senior Clinical Pharmacology Reviewer in the Office of Clinical Pharmacology, the Center for Drug Evaluation and Research, the Food and Drug Administration. He successfully reviewed numerous NDAs (including several NME NDAs and BLAs), NDA supplements, and IND submissions. He also contributed to several guidance document development and revision. His specific areas of expertise include clinical pharmacology, biopharmaceutics and regulatory sciences, and he has extensive experience in clinical pharmacology drug development plans/strategies and regulatory requirements. Derek received his Ph.D. from the University of California, San Francisco (UCSF) under Professor Leslie Z. Benet.

About Frontage Laboratories, Inc.

Frontage Laboratories, Inc. is a rapidly expanding global pharmaceutical R&D services company with offices in the U.S., Europe and China. Frontage provides research services to facilitate pharmaceutical discovery, development, preclinical and clinical research, commercialization and product launch, and assists its clients to resolve complex product development issues with a strong, experienced management team. The company's clients include four of the top ten largest pharmaceutical companies in the world. Frontage is experienced with developing new chemical entities, generic equivalent products, and supporting research for large molecules. For more information, please contact us at or visit us at

SOURCE Frontage Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
2. Codexis Appoints Singapore Laboratories Managing Director
3. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
4. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
5. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
6. Stiefel Laboratories Appoints Two New Members to Board of Directors
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
8. ARUP Laboratories Releases ARUP Consult(R) 2.0
9. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
10. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
11. Free White Paper Helps Biotech Laboratories Maintain a High Level of Infection Control
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: AEZ) ... remain fundamentally strong and highlights the following developments: ... DSMB recommendation to continue the ZoptEC Phase 3 ... final interim efficacy and safety data , ... with heavily pretreated castration- and Taxane-resistant prostate cancer ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):